Group Gp Lp Column III Purchases 15,100 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 15,100 shares of the stock in a transaction on Tuesday, January 6th. The stock was acquired at an average price of $19.89 per share, for a total transaction of $300,339.00. Following the completion of the purchase, the insider directly owned 989,893 shares in the company, valued at approximately $19,688,971.77. The trade was a 1.55% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Friday, December 5th, Group Gp Lp Column III acquired 30,884 shares of Surrozen stock. The shares were acquired at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III bought 5,266 shares of Surrozen stock. The stock was bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were bought at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

SRZN stock traded down $0.91 during mid-day trading on Thursday, reaching $19.06. The company had a trading volume of 14,409 shares, compared to its average volume of 76,400. The stock has a 50 day simple moving average of $17.88 and a two-hundred day simple moving average of $13.47. The company has a market capitalization of $163.34 million, a price-to-earnings ratio of -0.85 and a beta of 0.58. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, equities analysts predict that Surrozen, Inc. will post -8.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Stempoint Capital LP boosted its stake in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the period. Stonepine Capital Management LLC raised its holdings in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after acquiring an additional 20,247 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after acquiring an additional 47,468 shares during the period. Acuta Capital Partners LLC grew its holdings in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after purchasing an additional 8,415 shares in the last quarter. Finally, Braidwell LP acquired a new stake in shares of Surrozen during the 2nd quarter worth $1,252,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Surrozen currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.